Pharvaris to Present at SVB Securities Global Biopharma Conference
08 February 2023 - 10:50PM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced that
management will present at the SVB Securities Global Biopharma
Conference taking place virtually from February 14–16, 2023.
Pharvaris’ presentation will take place on Wednesday, February
15, at 2:40 p.m. CEST (8:40 a.m. EST). A live audio webcast will be
available on the Investors section of the Pharvaris website at:
https://ir.pharvaris.com/news-events/events-presentations. A replay
will be available on Pharvaris’ website for 30 days following the
presentation.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE safe, effective, and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
ContactMaryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2024 to May 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From May 2023 to May 2024